Overview of Financial Performance for XOMA Royalty Corporation
XOMA Royalty Corporation, known for its unique role in biotech royalty aggregation, has recently shared its financial results for the third quarter of 2024. With an impressive series of strategic movements, including the acquisition of new assets and partnerships, the company is steadfast in its mission to enhance human health.
Recent Achievements in Drug Development
A significant highlight from this quarter is the FDA approval of Zevra’s MIPLYFFA™ (arimoclomol), which now stands as the sixth commercial asset in XOMA Royalty’s portfolio. MIPLYFFA™ is the first FDA-approved treatment specifically for patients grappling with Niemann-Pick disease Type C, marking a pivotal moment for both Zevra and XOMA. This approval strengthens XOMA's commercial royalty portfolio, showcasing the company’s strategic focus on acquiring sustainable cash flow streams from impactful drug developments.
Expanding the Asset Base
Another strategic highlight is XOMA's acquisition of a 50 percent economic interest in TWIST Bioscience’s substantial portfolio, which comprises over 60 early-stage assets across approximately 30 partnerships. This expansion not only diversifies XOMA's risk but also solidifies its positioning in the biotech sector. CEO Owen Hughes emphasized the company’s balanced approach, focusing on acquiring royalty economics throughout the drug development lifecycle.
Financial Results Overview
In terms of financial performance, XOMA Royalty recorded total revenues of $7.2 million for the third quarter of 2024, a notable increase from $0.8 million reported in the same quarter of the previous year. This marked growth highlights the effectiveness of the company's strategic initiatives to enhance its revenue potential.
Expenditures and Investments
Research and development (R&D) expenses saw a rise to $0.8 million, closely linked to expenses associated with the KIN-3248 clinical trial, an asset gained during the Kinnate acquisition. General and administrative (G&A) expenses also surged to $8.0 million, up from $6.4 million, largely driven by costs related to the Kinnate acquisition.
Cash Flow and Dividends
XOMA's cash receipts hit $9.9 million in the third quarter, totaling $42.3 million for the first nine months of 2024. As of September 30, 2024, XOMA held cash and cash equivalents of $146.8 million, down from $159.6 million at the close of 2023. In terms of shareholder initiatives, the company paid out $1.4 million in dividends on its preferred stock, further demonstrating its commitment to returning value to shareholders.
Strategic Future Directions
Looking ahead, XOMA anticipates several important events in 2024. Notably, Takeda will host an R&D day focusing on late-stage pipeline developments, which will feature discussions on mezagitamab. XOMA is committed to remaining at the forefront of the biotech industry by strategically expanding its portfolio and maintaining diverse income streams from its partnerships.
About XOMA Royalty Corporation
XOMA Royalty Corporation plays a critical role in the biotech sector as a royalty aggregator, acquiring future revenue rights associated with therapeutic candidates licensed to biotech firms. This model supports fintech growth in biotech, providing sellers with much-needed funding without dilution. XOMA's portfolio continues to grow, reflecting its expertise and commitment in this niche market.
Frequently Asked Questions
What is XOMA Royalty Corporation's primary business?
XOMA Royalty Corporation operates as a biotechnology royalty aggregator, focusing on acquiring future revenue rights from therapeutic candidates in development.
What were the total revenues for XOMA in the third quarter of 2024?
XOMA reported total revenues of $7.2 million for the third quarter of 2024, a significant increase from previous years.
What recent approvals have contributed to XOMA’s portfolio growth?
The recent FDA approval of Zevra’s MIPLYFFA™ (arimoclomol) is a significant addition to XOMA's growing commercial royalty portfolio.
How much cash did XOMA receive in royalty payments this quarter?
In the third quarter, XOMA received $9.9 million in cash from royalty and commercial payments.
Who can I contact for more information about XOMA Royalty Corporation?
For investor inquiries, contact Juliane Snowden at +1-646-438-9754 or email juliane.snowden@xoma.com. For media inquiries, contact Kathy Vincent at +1-310-403-8951 or email kathy@kathyvincent.com.
